Trials / Unknown
UnknownNCT04627116
An Ascending, Multiple-Dose, Safety and Tolerability Study of Tecarfarin in Healthy Chinese Volunteers
A Multiple-Dose, Safety and Tolerability、PK/PD Study of Tecarfarin in Healthy Chinese Volunteers
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Lee's Pharmaceutical Limited · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
The subjects will be admitted to the Phase I Clinical Research Center on day -1. Subjects received once-daily doses of Tecarfarin for up to 14 days.Subjects can leave the Phase I Clinical Research Center on the day 21.And returned to the research center for follow-up on the day 28 and 35.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tecarfarin | Ten (10) healthy Chinese subjects received once-daily doses of Tecarfarin on fasting every morning for 14 days. |
Timeline
- Start date
- 2020-04-19
- Primary completion
- 2020-12-05
- Completion
- 2020-12-30
- First posted
- 2020-11-13
- Last updated
- 2020-11-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04627116. Inclusion in this directory is not an endorsement.